Martin Shkreli may have landed himself in more trouble with the law—and bought a longer prison sentence in the process. After reports that the “pharma bro” has been running a biotech from behind bars, the feds launched an investigation. More: Shkreli's jail-cell
read moreCellectis is building a 14,000-square-foot facility in Paris to produce clinical supplies, but the French biotech will also outfit a facility nearly six times that size in the U.S. as it looks towards commercial production of its CAR-T treatments. More: French
read moreGlaxoSmithKline’s ViiV Healthcare has already shown that a two-drug HIV regimen can stand up with its three-drug competitors. But now it has data showing a pairing can do the same with dosing just once per month. More: Glaxo's ViiV touts
read moreAnalysts welcomed Roche’s $4.8 billion takeover of Spark Therapeutics because of Spark’s novel gene therapy platform and potential enhancements in hemophilia and eye disease. But the acquisition didn’t come easy. More: Roche fought through a bidding war to land its Spark
read moreSanofi’s dengue ambitions are all but dashed in the Philippines, but the company still hopes its Dengvaxia vaccine can deliver the goods elsewhere. Those hopes took another hit, though, with a lukewarm reception from the FDA’s expert advisers. More: Sanofi's Dengvaxia faces
read moreUS regulators have accepted Sanofi’s Dupixent for Priority Review as a treatment for rhinosinusitis with nasal polyps. More: FDA grants Dupixent Priority Review for sinusitis Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals